Search - tctmd.com

Displaying 561 - 580 of 745

Sort: Relevancy | Date

Clinical Leaflet Thrombosis After TAVR Tied to Cardiogenic Shock and Death

News Conference News ESC 2017

Leaflet Thrombosis After TAVR Tied to Cardiogenic Shock and Death

Yael L. Maxwell

September 01, 2017

IMPACT-AF: Education, Feedback Boost Oral Anticoagulation Use for A-fib

News Conference News ESC 2017

IMPACT-AF: Education, Feedback Boost Oral Anticoagulation Use for A-fib

August 30, 2017

CHANGE DAPT: Study Contests Benefit of Ticagrelor Over Clopidogrel After PCI in ACS

News Conference News ESC 2017

CHANGE DAPT: Study Contests Benefit of Ticagrelor Over Clopidogrel After PCI in ACS

August 30, 2017

News Industry News

RE-DUAL PCI™ Results Offer Favorable New Safety Data on Pradaxa®

August 28, 2017

Ultra-Low LDL Levels? FOURIER Suggests Efficacy of Evolocumab

News Conference News ESC 2017

Ultra-Low LDL Levels? FOURIER Suggests Efficacy of Evolocumab

Michael O'Riordan

August 28, 2017

Dual Antithrombotic Approach in Patients With A-fib Undergoing PCI Boosted in RE-DUAL PCI

News Conference News ESC 2017

Dual Antithrombotic Approach in Patients With A-fib Undergoing PCI Boosted in RE-DUAL PCI

August 27, 2017

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

News Conference News ESC 2017

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

Michael O'Riordan

August 27, 2017

COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease

News Conference News ESC 2017

COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease

August 27, 2017

Evolocumab Not Cost-Effective at Current List Price

News Daily News

Evolocumab Not Cost-Effective at Current List Price

Michael O'Riordan

August 23, 2017

ESC 2017: In Tragedy’s Wake, Cardiology’s Biggest Congress Forges On, With Hotly Anticipated Trials

News Opinion Editor's Corner ESC 2017

ESC 2017: In Tragedy’s Wake, Cardiology’s Biggest Congress Forges On

August 18, 2017

In Case of Emergency: Don’t Rely on ‘Normal’ Range Assays With DOACs

News Daily News

In Case of Emergency: Don’t Rely on ‘Normal’ Range Assays With DOACs

August 10, 2017

Money-Back Guarantee for Evolocumab Has Little Impact on Cost-Effectiveness

News Daily News

Money-Back Guarantee for Evolocumab Has Little Impact on Cost-Effectiveness

Michael O'Riordan

August 08, 2017

CKD Patients Undergoing PCI Much Less Likely to Receive Potent P2Y12 Inhibition

News Daily News

CKD Patients Undergoing PCI Much Less Likely to Receive Potent P2Y12 Inhibition

Michael O'Riordan

August 04, 2017

Women With A-fib Less Likely to Get Oral Anticoagulants Regardless of Risk

News Daily News

Women With A-fib Less Likely to Get Oral Anticoagulants Regardless of Risk

August 03, 2017

Many Stroke Patients Stop Statins or Never Start, With Dire Consequences

News Daily News

Many Stroke Patients Stop Statins or Never Start, With Dire Consequences

Michael O'Riordan

August 02, 2017

‘Remnant’ Cholesterol Linked With CVD Risk, Even When LDL Levels Are Low

News Daily News

‘Remnant’ Cholesterol Linked With CVD Risk, Even When LDL Levels Are Low

Michael O'Riordan

August 01, 2017

How SGLT2 Inhibitors Help the Heart: Biomarker Study Offers Clues

News Daily News

How SGLT2 Inhibitors Help the Heart: Biomarker Study Offers Clues

August 01, 2017

Staying on Statins After an Adverse Event Lowers Risks of Death, MI or Stroke

News Daily News

Staying on Statins After an Adverse Event Lowers Risks of Death, MI or Stroke

Michael O'Riordan

July 25, 2017

Hormone Therapies May Have Adverse CV Effects in Transgender Adults

News Daily News

Hormone Therapies May Have Adverse CV Effects in Transgender Adults

July 24, 2017

Long-term Ticagrelor Post-MI of ‘Intermediate Value’: Cost-Effectiveness Study

News Daily News

Long-term Ticagrelor Post-MI of ‘Intermediate Value’: Cost-Effectiveness Study

July 24, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.